newsfilter
← Latest News
GlobeNewswire·

Portage Biotech Reports Fiscal Year-Ended March 31, 2024 Financial Results and Business Update

Exploration and evaluation of strategic alternatives continuePausing patient enrollment in the ADPORT-601 clinical trial (adenosine 2A and 2B inhibitors)Discontinuing the iNKT clinical trial for PORT-2 WESTPORT,